RedHill Biopharma Ltd.
RDHL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $15,305 | $18,916 | $17,377 | $240,079 |
| - Cash | $4,617 | $5,569 | $19,968 | $29,474 |
| + Debt | $356 | $1,173 | $122,691 | $87,812 |
| Enterprise Value | $11,044 | $14,520 | $120,100 | $298,417 |
| Revenue | $8,043 | $6,530 | $61,800 | $85,757 |
| % Growth | 23.2% | -89.4% | -27.9% | – |
| Gross Profit | $4,851 | $3,071 | $28,463 | $36,351 |
| % Margin | 60.3% | 47% | 46.1% | 42.4% |
| EBITDA | -$7,594 | $26,273 | -$22,182 | -$63,028 |
| % Margin | -94.4% | 402.3% | -35.9% | -73.5% |
| Net Income | -$8,268 | $23,916 | -$71,669 | -$97,744 |
| % Margin | -102.8% | 366.2% | -116% | -114% |
| EPS Diluted | -7 | 46 | -600 | -1,000 |
| % Growth | -115.2% | 107.7% | 40% | – |
| Operating Cash Flow | -$9,369 | -$35,820 | -$29,185 | -$65,047 |
| Capital Expenditures | -$9 | -$11 | -$198 | -$115 |
| Free Cash Flow | -$9,378 | -$35,831 | -$29,383 | -$65,162 |